4.47
                                            Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Will Vanda Pharmaceuticals Inc. (VM4) stock see insider accumulationJuly 2025 Big Picture & Step-by-Step Swing Trade Plans - newser.com
Will Vanda Pharmaceuticals Inc. stock benefit from infrastructure spending2025 Market Sentiment & Smart Investment Allocation Tips - newser.com
Chart based analysis of Vanda Pharmaceuticals Inc. trendsBull Run & Low Drawdown Trading Techniques - newser.com
How supply shortages influence Vanda Pharmaceuticals Inc. (VM4) stockJuly 2025 Volume & Community Consensus Stock Picks - newser.com
Is Vanda Pharmaceuticals Inc. (VM4) stock considered safe havenDip Buying & Verified Momentum Stock Watchlist - newser.com
Visualizing Vanda Pharmaceuticals Inc. stock with heatmaps2025 Price Targets & AI Driven Stock Movement Reports - newser.com
Is Vanda Pharmaceuticals Inc. stock safe for conservative investorsWeekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
Will Vanda Pharmaceuticals Inc. stock recover after recent drop2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
How Vanda Pharmaceuticals Inc. stock performs in interest rate cycles2025 Top Decliners & Smart Swing Trading Techniques - newser.com
Can Vanda Pharmaceuticals Inc. stock deliver surprise earnings beatWeekly Trade Report & High Yield Equity Trading Tips - newser.com
Backtesting results for Vanda Pharmaceuticals Inc. trading strategiesQuarterly Trade Report & Proven Capital Preservation Methods - newser.com
Smart tools for monitoring Vanda Pharmaceuticals Inc.’s price action2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com
Can Vanda Pharmaceuticals Inc. recover in the next quarterMarket Activity Report & Fast Moving Stock Watchlists - newser.com
Will Vanda Pharmaceuticals Inc. (VM4) stock remain on Wall Street radar2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
FY2025 EPS Estimates for VNDA Boosted by Cantor Fitzgerald - MarketBeat
News impact scoring models applied to Vanda Pharmaceuticals Inc.Portfolio Update Summary & Free Fast Gain Swing Trade Alerts - newser.com
Assessing Vanda Pharmaceuticals (VNDA) Valuation After Q3 2025 Growth and Updated FDA Milestones - Yahoo Finance
How institutional buying supports Vanda Pharmaceuticals Inc. stock2025 Top Decliners & Smart Swing Trading Techniques - newser.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Vanda Pharmaceuticals Reports Strong Sales Growth and Pipeline Progress - MSN
Cantor Fitzgerald Cuts Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target to $11.00 - MarketBeat
Jim Cramer on Vanda Pharmaceuticals: “I’m Going to Bless That One as Your Spec” - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Q3 Earnings Preview - MSN
Published on: 2025-10-31 05:46:53 - newser.com
Applying big data sentiment scoring on Vanda Pharmaceuticals Inc.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
Real time pattern detection on Vanda Pharmaceuticals Inc. stockQuarterly Profit Review & Consistent Return Strategy Ideas - newser.com
Vanda Pharmaceuticals Inc. stock retracement – recovery analysis - newser.com
Vanda Pharmaceuticals (VNDA): Forecasts See Earnings Growth of 68.5% Annually Heading Into Earnings Season - Sahm
Vanda Pharmaceuticals (VNDA): Revenue Projected to Grow 22.7% Annually, Profitability in Focus Ahead of Earnings - Yahoo Finance
Vanda Pharmaceuticals Inc (VNDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Vanda Pharmaceuticals Inc. (VNDA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Vanda Pharmaceuticals Inc (VNDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses - GuruFocus
VNDA Analyst Rating Update: Cantor Fitzgerald Adjusts Price Target | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Inc. SEC 10-Q Report - TradingView
        Apri su Yahoo
        |
        Apri su Google
            |
            Aperto in Finviz
        |
        Apri in MarketWatch
            |
            Aperto a EDGAR    
        |
        Aperto su Reuters
    
    
                Capitalizzazione:
                 
                  | 
                Volume (24 ore):